Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Delayed Administration Of Dexrazoxane Provides Cardioprotection For Patients With Advanced Breast Cancer Treated With Doxorubicin-containing Therapy.

S. Swain, F. Whaley, M. Gerber, M. Ewer, J. Bianchine, R. Gams
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
PURPOSE To assess whether dexrazoxane (DZR) given after a cumulative doxorubicin dose of 300 mg/m2 confers cardioprotection in patients with advanced breast cancer treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC). PATIENTS AND METHODS In two multicenter studies (088001 and 088006), patients were randomized to receive FAC and placebo (PLA) versus FAC and DZR. After a protocol amendment, all patients received open-label DZR after they had reached a cumulative doxorubicin dose of 300 mg/m2. Two groups were compared: 99 patients randomized to the PLA arms before the amendment who received FAC and PLA for at least seven courses (PLA group), and 102 patients randomized to the PLA arms after the amendment who received FAC and PLA for six courses followed by open-label DZR (PLA/DZR group). RESULTS The hazards ratio of PLA to PLA/DZR was 3.5 (95% confidence interval [CI], 2.2 to 5.7; P < .001, logrank and generalized Wilcoxon tests) for the doxorubicin dose at any cardiac event, ejection fraction changes, or congestive heart failure (CHF). The hazards ratio of PLA to PLA/DZR was 13.1 (95% CI, 3.7 to 46.0; P < .001, logrank and generalized Wilcoxon tests) for the doxorubicin dose at the development of CHF. The overall incidence of CHF in the PLA/DZR group was 3%, compared with 22% in the PLA group (P < .001, Fisher's exact test). Twenty-six percent of PLA/DZR patients received at least 15 courses of therapy, compared with 5% of patients in the PLA group. These results do not appear to be attributable to a time trend. CONCLUSION DZR is a highly effective cardioprotective agent when used in patients with advanced breast cancer who continue to receive doxorubicin-based chemotherapy after a cumulative doxorubicin dose of 300 mg/m2 has been reached.
This paper references

This paper is referenced by
Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.
Cyrus Chargari (2011)
Liposomal anthracyclines for improved cardiac tolerability
P. Schmid (2001)
Cardiovascular Complications of Chemotherapy: Anthracycline Cardiotoxicity
R. Russell (2014)
A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
P. Spallarossa (2016)
Improving Aav Transduction Efficiency In Retinal Bipolar Cells For Optogenetic Vision Restoration
Shengjie Cui (2018)
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
K. Hellmann (2000)
Freireich's laws in the treatment of sarcomas.
R. Benjamin (1997)
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
Treatment for advanced metastatic breast cancer, after use the total recommended cumulated dose of doxorubicin
Anna Majstrak (2010)
Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat.
B. Hasinoff (1999)
Diagnostic Aspects of Cardiovascular Toxicity of Antitumor Drugs
M. Ewer (2010)
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
S. Giordano (2002)
Dietary red palm oil protects the heart against the cytotoxic effects of anthracycline
A. Wergeland (2011)
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
Dexrazoxane Protects Breast Cancer Patients With Diabetes From Chemotherapy-Induced Cardiotoxicity
Fangyi Sun (2015)
Anthracycline and Peripartum Cardiomyopathies.
Joshua A. Cowgill (2019)
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
L. Schuchter (2002)
A Review of Recent Results Addressing the Potential Interactions of Antioxidants with Cancer Drug Therapy
J. B. Block (2001)
Anthracycline cardiotoxicity
R. Jones (2006)
Dexrazoxane: A New Cardioprotective Agent
B. D. Abbott (1998)
Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment
Y. Saleh (2020)
Cardiac profiles of liposomal anthracyclines
M. Theodoulou (2004)
Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer.
S. Campos (2003)
Dexrazoxane pre‐treatment protects skinned rat cardiac trabeculae against delayed doxorubicin‐induced impairment of crossbridge kinetics
Evert L de Beer (2002)
Stratégie de dépistage précoce de la toxicité cardiaque secondaire aux anthracyclines et thérapies moléculaires ciblées
Agathe Potier (2016)
A Phase II Trial of Vinorelbine and Pegylated Liposomal Doxorubicin in Patients With Pretreated Metastatic Breast Cancer
L. Chow (2007)
Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures.
L. M. Antunes (1999)
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent
P. E. Schroeder (2004)
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
M. Tetef (2001)
Novel anticancer agents : strategies for discovery and clinical testing
A. A. Adjei (2006)
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
S. Swain (2003)
Chemical screening identifies the β-Carboline alkaloid harmine to be synergistically lethal with doxorubicin
Reham Atteya (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar